Zhang, Lin http://orcid.org/0000-0001-8463-2141
Woltering, Iris
Holzner, Mathias
Brandhofer, Markus
Schaefer, Carl-Christian
Bushati, Genta
Ebert, Simon
Yang, Bishan
Muenchhoff, Maximilian
Hellmuth, Johannes C.
Scherer, Clemens
Wichmann, Christian
Effinger, David
Hübner, Max
El Bounkari, Omar
Scheiermann, Patrick
Bernhagen, Jürgen http://orcid.org/0000-0003-2996-2652
Hoffmann, Adrian http://orcid.org/0009-0000-0661-2321
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1123-A3, INST 409/209-1 FUGG, EXC 2145 SyNergy—ID 390857198)
LMU Munich (Metiphys scholarship)
LMU Munich-DFG excellence (LMUexc) program (Knowledge Transfer Fund)
Friedrich-Baur-Stiftung (72/20)
Klinikum der Universität München
Article History
Received: 26 March 2024
Revised: 4 June 2024
Accepted: 27 June 2024
First Online: 11 July 2024
Declarations
:
: C.S. received speaker honoraria from AstraZeneca on topics outside of the submitted work. J.B. and O.E.B. are inventors on patent applications related to anti-MIF strategies. All other authors declare no competing interests.
: Studies abide by the Declaration of Helsinki principles and all patients provided informed consent. Studies were approved by ethics approvals 18-104 and 23-0639 of the Ethics Committee of LMU Munich, which encompasses the use of anonymized tissue and blood specimens for research purposes. The study of patient samples from the COVID-19 Registry of the LMU University Hospital Munich (CORKUM, WHO trial ID DRKS00021225) was approved by the Ethics Committee of LMU Munich (project numbers: 20-245 and 23-0711).
: N/A.